Margarita Majem, MD, PhD, a faculty member in the Department of Medical Oncology at the Hospital de la Santa Creu i Sant Pau, discusses the safety profile of osimertinib (Tagrisso) in patients with 

-mutated non–small cell lung cancer (NSCLC).

Osimertinib continues to showcase a favorable safety profile, similar to what has been observed in previous studies such as the ADAURA (NCT02511106) or FLAURA (NCT02296125) trials, Majem says. Moreover, the safety profile of the third-generation TKI appears to better than what has been observed with first- and second-generation TKIs, Majem notes.

It’s important that this therapy is tolerable, as patients will receive treatment for up to 3 years. Thus far, osimertinib appears to be a beneficial option for this patient population, as it allows for extended treatment without dose interruption or reduction due to toxicity, Majem concludes.

Videos

Margarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.


Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLC

Margarita Majem, MD, PhD, a faculty member in the Department of Medical Oncology at the Hospital de la Santa Creu i Sant Pau, discusses the patient-reported outcomes with osimertinib (Tagrisso) in 

-mutated non–small cell lung cancer (NSCLC) from the pivotal phase 3 ADAURA trial.

Results from the phase 3 ADAURA trial, which examined the use of osimertinib in resected, 

-mutant NSCLC, indicated that patients who received osimertinib had significantly longer disease-free survival compared to patients who received a placebo.

At baseline, patients had nearly the same mean value of quality of life (QoL) as the general population, according to Majem, who virtually presented the findings during the 

. When patients were treated with osimertinib, QoL was maintained across all domains evaluated in the analysis, Majem concludes.

Margarita Majem, MD, PhD, discusses the patient-reported outcomes with osimertinib in EGFR-mutated non–small cell lung cancer from the pivotal phase 3 ADAURA trial.



Margarita Majem

Articles

Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLC

Dr. Majem on Patient-Reported Outcomes With Osimertinib in EGFR+ NSCLC